#USA #New York #Hoth Therapeutics #HT-KIT #GIST

Hoth Therapeutics Reveals Game-Changing Results in GIST Treatment

In a recent announcement, Hoth Therapeutics, Inc. (NASDAQ HOTH), a biopharmaceutical company focused on innovative therapies, shared groundbreaking preclinical results concerning HT-KIT—a novel treatment for gastrointestinal stromal tumors (GIST). This therapy has shown remarkable promise in not only reducing tumor size but also in inducing substantial cell death in aggressive cancer models.

Key Findings from the Study

The preclinical study yielded several significant findings that highlight HT-KIT's potential:

1. Rapid Induction of Tumor Cell Death: One of the most striking outcomes was the induction of tumor cell death just 24 hours after treatment with HT-KIT. Even at lower doses, a notable reduction in cell viability was witnessed after 72 hours of administration.

2. Inhibition of Tumor Cell Proliferation: HT-KIT demonstrated its ability to significantly hinder the growth of GIST-T1 cells. This was confirmed both by a reduction in cell counts and decreased fluorescence intensity in proliferation assays, which measure cell growth effectively.

3. Marked Reduction of Tumor Volume in Mouse Models: In experiments using humanized xenograft models, the administration of HT-KIT (12.5 mg/kg IV every three days) led to a significant decline in tumor growth. The statistically significant differences from day eight showed HT-KIT's increasing effectiveness over time.

4. Consistent Tumor Size Reduction: Tumors extracted from treated mice were not only smaller but also lighter compared to those in the control group, reinforcing the observed volume metrics.

Hoth Therapeutics' approach of targeting the KIT mutations, which are known to be key drivers in the progression of GIST, demonstrates HT-KIT's potential as a transformative treatment option. "These findings represent a crucial milestone in the development of HT-KIT for GIST patients," noted Robb Knie, CEO of Hoth Therapeutics. He emphasized the ability of HT-KIT to potentially overcome existing therapeutic resistance seen with current treatments, especially against tyrosine kinase inhibitors (TKIs).

Advantages of HT-KIT

The unique advantage presented by HT-KIT lies in its design to obstruct KIT receptor activity directly, as opposed to merely inhibiting downstream signaling pathways. This distinct mechanism exhibits HT-KIT's potential to offer an innovative solution for patients battling this challenging condition. Given the limitations of current therapies, the development of HT-KIT could introduce a much-needed option in oncology.

Future Steps in Development

Following these compelling preclinical results, Hoth Therapeutics is committed to pushing HT-KIT closer to clinical application. The company is embarking on further preclinical studies to bolster the evidence for HT-KIT's safety and efficacy, with plans to initiate discussions with regulatory bodies regarding the pathway to human trials.

Company Overview

Hoth Therapeutics, Inc. stands at the forefront of industry innovation, dedicated to enhancing patient quality of life through the development of novel therapeutics. Their patient-centric research model aims to uncover impactful treatment strategies by collaborating with a network of scientists and healthcare experts. Further details on their ongoing research and product pipeline can be found on their website: Hoth Therapeutics.

In summary, the promising results from HT-KIT's preclinical trials signify Hoth Therapeutics' dedication to advancing treatment options for patients affected by GIST, setting a foundation for future successes in combating this aggressive cancer.